**Supplementary Table 4. Change of Clinical Indices Before and After SOF-VEL Treatment.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Pre-treatment**N(%)/N(%) | **Treatment for 12w**N(%)/N(%) | **SVR12**N(%)/N(%) | **P value** |
| HCV RNA(negative/positive) | 0(0.0)/80(100.0) | 79(98.8)/1(0.2) | 76(95.0)/4(4.0) | **<0.001** |
| Liver Function(<LoD/>LoD) | 7(8.8)/73(91.2) | 24(30.0)/56(70.0) | 29(36.3)/51(63.7) | **<0.001** |
| Child-Pugh(A/B+C) | 69(86.3)/11(13.7) | 68(85.0)/12(15.0) | 65(81.3)/15(18.7) | 0.666 |
| FIB-4 score(<3.25/≥3.25) | 42(52.5)/38(47.5) | 53(66.3)/27(33.7) | 56(70)/24(30) | 0.054 |
| AFP(normal/abnormal) | 71(88.8)/9(11.2) | 70(87.5)/10(12.5) | 77(96.3)/3(3.7) | 0.116 |

Notes: SVR12 referred to sustained virological response after stopping SOF-VEL treatment for 12 weeks, which meant that viral load was below the detection limit 12 weeks after the end of the treatment. AFP: alpha-fetaprotein; FIB-4:the fibrosis index based on four factors, FIB4=Age×AST/(Platelet×sqr(ALT)); Age in years old, AST in U/L (Normal range: 15~ 40U/L), Platelet count in 10³/µL (Normal range: 125~ 350 × 10³/µL), ALT in U/L (Normal range: 9 ~ 50 U/L). Points > 3.25: Cirrhosis most likely. LoD: limit of detection